Hiroki Kobayashi et al.
Biochemical and biophysical research communications, 467(1), 121-127 (2015-09-26)
Combining glycolytic inhibition with other anti-cancer therapies is a potential approach to treating cancer. In this context, we attempted to identify genes that determine sensitivity to 2-deoxyglucose (2DG), a glycolytic inhibitor, in cancer cells using pooled shRNA libraries targeting ∼15,000